A Phase II, Single Arm, Open Label Study Of NKTR-102 In Bevacizumab-Resistant High Grade Glioma
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2015
At a glance
- Drugs Etirinotecan pegol (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 10 Jun 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov record.
- 25 Nov 2014 Planned End Date changed from 1 Jul 2014 to 1 nov 2015 as reported by ClinicalTrials.gov.
- 25 Nov 2014 Planned primary completion date changed from 1 Jul 2014 to 1 May 2015 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History